Skip to main content
NCBI home page
The Texas Heart Institute Journal logoLink to The Texas Heart Institute Journal
. 1991;18(1):34–40.

Double valve Implantation

Long-term Evaluation of 8 Different Bioprostheses

Paolo Stassano 1, Vito Mannacio 1, Antonino Musumeci 1, Alessandro Golino 1, Piero Maida 1, Vincenzo Ferrigno 1, Gaetano Buonocore 1, Nicola Spampinato 1
PMCID: PMC324958  PMID: 15227506

Abstract

From January 1976 through December 1987, 194 patients with a mean age of 43.3 ± 13.7 years (range, 11 to 74 years) underwent double (mitral and aortic) replacement of native valves with 8 types of bioprostheses: Carpentier-Edwards, 127 valves; Hancock, 76 valves; Liotta-Bioimplant, 57 valves; Ionescu-Shiley, 53 valves; Vascor, 27 valves; Carpentier-Edwards Pericardial, 22 valves; Angell-Shiley, 20 valves; and Implamedic, 6 valves. Concomitant cardiac procedures were performed in 25 patients (12.8%). There were 18 operative deaths (9.27%).

Our retrospective analysis was restricted to 352 bioprostheses implanted in the 176 patients who survived surgery and were considered at risk for valve tissue failure. The overall cumulative duration of follow-up was 1,174.1 patient-years (range, 1 to 13 years). The durations of follow-up for specific valves were: Carpentier-Edwards, 920.2 valve-years; Hancock, 383.8 valve-years; Liotta-Bioimplant, 310.2 valve-years; Ionescu-Shiley, 357.7 valve-years; Vascor, 131.2 valve-years; Carpentier-Edwards Pericardial, 52.0 valve-years; Angell-Shiley, 167.0 valve-years; and Implamedic, 31.0 valve-years.

Thirty patients had thromboembolic accidents, for a linearized incidence of 2.5% per patient-year. At 13 years, the actuarial freedom from thromboembolic accidents was 85.8% ± 10.7%.

Nine patients had endocarditis, for a linearized incidence of 0.7% per patient-year. At 13 years, the actuarial freedom from endocarditis was 92.0% ± 1.5%.

Twenty-four patients had valve tissue failure, for a cumulative linearized incidence of 1.87% per valve-year. The cumulative actuarial probability of freedom from valve tissue failure was 78.6% ± 3.7% at 10 years and 51.2% ± 10.7% at 13 years. The 24 patients with valve tissue failure all underwent reoperation: 20 of these had double valve replacement, 3 had aortic valve replacement alone, and 1 had mitral valve replacement alone. The mean interval between initial valve implantation and reoperation was 66.9 ± 28.8 months. At reoperation, the hospital mortality was 15.1% (5 patients).

This study showed that the long-term results of valve implantation are not significantly influenced by either prosthesis design or material. Moreover, the incidence of degenerative change was similar in the aortic and mitral positions. (Texas Heart Institute Journal 1991;18:34-40)

Keywords: Aortic valve

Keywords: bioprosthesis

Keywords: heart valve diseases

Keywords: heart valve prosthesis

Keywords: mitral valve

Keywords: prosthesis failure

Keywords: reoperation

Full text

PDF
34

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bolooki H., Mallon S., Kaiser G. A., Thurer R. J., Kieval J. Failure of Hancock xenograft valve: importance of valve position (4- to 9-year follow-up). Ann Thorac Surg. 1983 Sep;36(3):246–252. doi: 10.1016/s0003-4975(10)60124-5. [DOI] [PubMed] [Google Scholar]
  2. Borkon A. M., McIntosh C. L., Von Rueden T. J., Morrow A. G. Mitral valve replacement with the Hancock bioprosthesis: five- to ten-year follow-up. Ann Thorac Surg. 1981 Aug;32(2):127–137. doi: 10.1016/s0003-4975(10)61019-3. [DOI] [PubMed] [Google Scholar]
  3. Bortolotti U., Milano A., Thiene G., Guerra F., Mazzucco A., Talenti E., Gallucci V. Long-term durability of the Hancock porcine bioprosthesis following combined mitral and aortic valve replacement: an 11-year experience. Ann Thorac Surg. 1987 Aug;44(2):139–144. doi: 10.1016/s0003-4975(10)62025-5. [DOI] [PubMed] [Google Scholar]
  4. Carpentier A., Dubost C., Lane E., Nashef A., Carpentier S., Relland J., Deloche A., Fabiani J. N., Chauvaud S., Perier P. Continuing improvements in valvular bioprostheses. J Thorac Cardiovasc Surg. 1982 Jan;83(1):27–42. [PubMed] [Google Scholar]
  5. Cipriano P. R., Billingham M. E., Miller D. C. Calcification of aortic versus mitral porcine bioprosthetic heart valves: a radiographic study comparing amounts of calcific deposits in valves explanted from the same patient. Am J Cardiol. 1984 Nov 1;54(8):1030–1032. doi: 10.1016/s0002-9149(84)80139-3. [DOI] [PubMed] [Google Scholar]
  6. Cohn L. H., Mudge G. H., Pratter F., Collins J. J., Jr Five to eight-year follow-up of patients undergoing porcine heart-valve replacement. N Engl J Med. 1981 Jan 29;304(5):258–262. doi: 10.1056/NEJM198101293040503. [DOI] [PubMed] [Google Scholar]
  7. Craver J. M., Jones E. L., McKeown P., Bone D. K., Hatcher C. R., Jr, Kandrach M. Porcine cardiac xenograft valves: analysis of survival, valve failure, and explantation. Ann Thorac Surg. 1982 Jul;34(1):16–21. doi: 10.1016/s0003-4975(10)60846-6. [DOI] [PubMed] [Google Scholar]
  8. Gallo I., Ruiz B., Nistal F., Durán C. M. Degeneration in porcine bioprosthetic cardiac valves: incidence of primary tissue failures among 938 bioprostheses at risk. Am J Cardiol. 1984 Apr 1;53(8):1061–1065. doi: 10.1016/0002-9149(84)90637-4. [DOI] [PubMed] [Google Scholar]
  9. Hammond G. L., Geha A. S., Kopf G. S., Hashim S. W. Biological versus mechanical valves. Analysis of 1,116 valves inserted in 1,012 adult patients with a 4,818 patient-year and a 5,327 valve-year follow-up. J Thorac Cardiovasc Surg. 1987 Feb;93(2):182–198. [PubMed] [Google Scholar]
  10. Hartz R. S., Fisher E. B., Finkelmeier B., DeBoer A., Sanders J. H., Jr, Moran J. M., Michaelis L. L. An eight-year experience with porcine bioprosthetic cardiac valves. J Thorac Cardiovasc Surg. 1986 Jun;91(6):910–917. [PubMed] [Google Scholar]
  11. Jamieson W. R., Rosado L. J., Munro A. I., Gerein A. N., Burr L. H., Miyagishima R. T., Janusz M. T., Tyers G. F. Carpentier-Edwards standard porcine bioprosthesis: primary tissue failure (structural valve deterioration) by age groups. Ann Thorac Surg. 1988 Aug;46(2):155–162. doi: 10.1016/s0003-4975(10)65888-2. [DOI] [PubMed] [Google Scholar]
  12. Janusz M. T., Jamieson W. R., Allen P., Munro A. I., Miyagishima R. T., Tutassura H., Burr L. H., Gerein A. N., Tyers G. F. Experience with the Carpentier-Edwards porcine valve prosthesis in 700 patients. Ann Thorac Surg. 1982 Dec;34(6):625–633. doi: 10.1016/s0003-4975(10)60900-9. [DOI] [PubMed] [Google Scholar]
  13. Lakier J. B., Khaja F., Magilligan D. J., Jr, Goldstein S. Porcine xenograft valves. Long-term (60-89-month) follow-up. Circulation. 1980 Aug;62(2):313–318. doi: 10.1161/01.cir.62.2.313. [DOI] [PubMed] [Google Scholar]
  14. Magilligan D. J., Jr, Lewis J. W., Jr, Heinzerling R. H., Smith D. Fate of a second porcine bioprosthetic valve. J Thorac Cardiovasc Surg. 1983 Mar;85(3):362–370. [PubMed] [Google Scholar]
  15. Magilligan D. J., Jr, Lewis J. W., Jr, Tilley B., Peterson E. The porcine bioprosthetic valve. Twelve years later. J Thorac Cardiovasc Surg. 1985 Apr;89(4):499–507. [PubMed] [Google Scholar]
  16. Milano A. D., Bortolotti U., Mazzucco A., Guerra F., Stellin G., Talenti E., Thiene G., Gallucci V. Performance of the Hancock porcine bioprosthesis following aortic valve replacement: considerations based on a 15-year experience. Ann Thorac Surg. 1988 Aug;46(2):216–222. doi: 10.1016/s0003-4975(10)65902-4. [DOI] [PubMed] [Google Scholar]
  17. Milano A., Bortolotti U., Talenti E., Valfrè C., Arbustini E., Valente M., Mazzucco A., Gallucci V., Thiene G. Calcific degeneration as the main cause of porcine bioprosthetic valve failure. Am J Cardiol. 1984 Apr 1;53(8):1066–1070. doi: 10.1016/0002-9149(84)90638-6. [DOI] [PubMed] [Google Scholar]
  18. Oyer P. E., Stinson E. B., Reitz B. A., Miller D. C., Rossiter S. J., Shumway N. E. Long-term evaluation of the porcine xenograft bioprosthesis. J Thorac Cardiovasc Surg. 1979 Sep;78(3):343–350. [PubMed] [Google Scholar]
  19. Schoen F. J., Collins J. J., Jr, Cohn L. H. Long-term failure rate and morphologic correlations in porcine bioprosthetic heart valves. Am J Cardiol. 1983 Mar 15;51(6):957–964. doi: 10.1016/s0002-9149(83)80173-8. [DOI] [PubMed] [Google Scholar]
  20. Spampinato N., Stassano P., Cammarota A., Musumeci A., Mannacio V., Iorio D., Covino E. Bioprostheses at twelve years. J Card Surg. 1988 Sep;3(3 Suppl):383–390. doi: 10.1111/jocs.1988.3.3s.383. [DOI] [PubMed] [Google Scholar]
  21. Stassano P., Gagliardi C., Matarazzo L., Musumeci A., Spampinato N. The bioprosthetic valve of choice for high-risk patients: long-term results (up to 10 years). Tex Heart Inst J. 1985 Dec;12(4):311–314. [PMC free article] [PubMed] [Google Scholar]
  22. Stassano P., Iorio D., Gagliardi C., Spampinato N. Re: Low-profile bioprosthesis for mitral regurgitation associated with idiopathic hypertrophic subaortic stenosis. Cleve Clin Q. 1985 Fall;52(3):437–439. doi: 10.3949/ccjm.52.3.437. [DOI] [PubMed] [Google Scholar]

Articles from Texas Heart Institute Journal are provided here courtesy of Texas Heart Institute

RESOURCES